Stewart Fitzell @defense_investor: "𝗣𝘂𝗹𝗹𝗯𝗮𝗰𝗸𝘀 & 𝗣𝗿𝗼𝗳𝗶𝘁𝘀: 𝙃𝙤𝙬 𝙄'𝙢..."

Ireland

Edited

𝗣𝘂𝗹𝗹𝗯𝗮𝗰𝗸𝘀 & 𝗣𝗿𝗼𝗳𝗶𝘁𝘀: 𝙃𝙤𝙬 𝙄'𝙢 𝙣𝙖𝙫𝙞𝙜𝙖𝙩𝙞𝙣𝙜 𝙎𝙚𝙥𝙩𝙚𝙢𝙗𝙚𝙧 There’s plenty going on in the markets right now. I'll take a look at what's going on and how the portfolio has been performing. 👇 ▪️𝙐𝙎 𝙅𝙤𝙗𝙨 𝙉𝙪𝙢𝙗𝙚𝙧𝙨 𝙬𝙚𝙖𝙠𝙚𝙣𝙞𝙣𝙜 The latest U.S. jobs report was weak—just 22,000 jobs added and unemployment climbing to 4.3%, the highest since 2021. This is putting real pressure on the US Federal Reserve, with markets now expecting a rate cut in September, possibly as much as 50bp. (0.5%). US companies remain cautious on hiring and expansion, weighed down by tariffs and higher financing costs. Meanwhile, safe returns are drawing capital away from equities: the 30-year bond yield hit 5% this week, offering investors a compelling alternative. Inflation is still sticky, with CPI at 2.7%, keeping the Fed in a tough position. All eyes are on next week’s CPI report to set the tone for the September Fed meeting. ▪️𝙎𝙤𝙢𝙚 𝙡𝙞𝙜𝙝𝙩 𝙖𝙩 𝙩𝙝𝙚 𝙚𝙣𝙙 𝙤𝙛 𝙩𝙝𝙚 𝙩𝙪𝙣𝙣𝙚𝙡? Not everything is negative. The Institute for Supply Management services index rose to 52.0 in August, showing expansion in a sector that represents more than two-thirds of the U.S. economy. This resilience is an encouraging sign that the underlying economy is still holding up. Even so, with stocks near all-time highs and September historically a challenging month for equities, volatility is likely to stay elevated. Tech has remained relatively strong, supported by earnings momentum and the prospect of lower rates. While I’m cautious about stretched valuations in some cases, I'm also conscious that there's more room to grow - it's a fine balance. ▪️𝙋𝙤𝙧𝙩𝙛𝙤𝙡𝙞𝙤 𝘼𝙙𝙟𝙪𝙨𝙩𝙢𝙚𝙣𝙩𝙨 𝙖𝙣𝙙 𝙋𝙚𝙧𝙛𝙤𝙧𝙢𝙖𝙣𝙘𝙚 Earlier in the week I took some profits and made adjustments to the portfolio—reducing gold and trimming stocks I felt were due for a pullback, including $NVDA (NVIDIA Corporation) , $GOOG (Alphabet) , $MSFT (Microsoft) , and $AVAV (AeroVironment Inc.) . I added $LLY (Eli Lilly & Co) recently and may grow this position. Despite a difficult year, this pharma company looks to be at a turnabout point with strong demand for its weight-loss and diabetes treatments, a promising pipeline, and signs that weakness may already be priced in. 💸 We’re also heavier than usual on cash, which will be redeployed as opportunities develop. The cash is held within the portfolio / copy and copiers do not need to do anything. 𝙒𝙞𝙩𝙝 𝙙𝙞𝙨𝙘𝙞𝙥𝙡𝙞𝙣𝙚𝙙 𝙥𝙤𝙨𝙞𝙩𝙞𝙤𝙣𝙞𝙣𝙜 𝙖𝙣𝙙 𝙖𝙙𝙟𝙪𝙨𝙩𝙞𝙣𝙜, 𝙩𝙝𝙞𝙨 𝙥𝙤𝙧𝙩𝙛𝙤𝙡𝙞𝙤 𝙞𝙨 𝙪𝙥 +𝟮𝟱.𝟲% 𝙔𝙏𝘿 𝙫𝙚𝙧𝙨𝙪𝙨 𝙩𝙝𝙚 𝙎&𝙋 𝟱𝟬𝟬’𝙨 𝟭𝟬.𝟮% - 𝙖 𝙫𝙚𝙧𝙮 𝙘𝙡𝙚𝙖𝙧 𝙤𝙪𝙩𝙥𝙚𝙧𝙛𝙤𝙧𝙢𝙖𝙣𝙘𝙚 𝙞𝙣 𝙖 𝙘𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙞𝙣𝙜 𝙢𝙖𝙧𝙠𝙚𝙩. Stay patient, stay informed—& let the strategy work. 👍 Please like, comment & share - this really helps. Regards, Stewart 🔹️𝙋𝙤𝙧𝙩𝙛𝙤𝙡𝙞𝙤 𝙄𝙣𝙩𝙧𝙤𝙙𝙪𝙘𝙩𝙞𝙤𝙣 & 𝙁𝘼𝙌 etoro.tw/3BqjOb2 🔹️𝘾𝙤𝙥𝙮 𝙏𝙧𝙖𝙙𝙞𝙣𝙜: 𝙆𝙚𝙮 𝙄𝙣𝙛𝙤𝙧𝙢𝙖𝙩𝙞𝙤𝙣 etoro.tw/45vTQj5 ⚠️ Risk Warnings: Copy Trading does not amount to investment advice | Your capital is at risk | The value if your investments may go up or down. | Past performance is not indicative of future results.

5 Mentioned

NVDA

GOOG

MSFT

AVAV

LLY

Strictly Necessary Cookies

Performance Cookies

Functional Cookies

Targeting Cookies